What's in TWI PHARMS's pipeline?

TWI PHARMS has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with TWI PHARMS's portfolio?

Top competitors by shared drug class: , Uswm.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/twi-pharms.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

TWI PHARMS — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TWI PHARMS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Tenoretic 100	ATENOLOL	marketed	beta-Adrenergic Blocker [EPC]	Adenosine receptor A3	Neuroscience	1981-01-01

Therapeutic area mix

Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Uswm · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TWI PHARMS:

Cite this brief

Drug Landscape (2026). TWI PHARMS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/twi-pharms. Accessed 2026-06-10.